On Friday, Shares of Constellium NV (NYSE:CSTM), gained 5.56% to $7.02.
Constellium N.V., stated results for the second quarter ended June 30, 2015. Highlights below are in comparison to the second quarter of 2014.
- Shipments of 386 thousand metric tons, up 38%
- Revenue of €1.375 billion, up 49%
- Adjusted EBITDA of €93 million, counting €19 million from Muscle Shoals adjusted for Midwest premium impact
- Strong Adjusted Free Cash Flow of €72 million and liquidity of €690 million
- Automotive rolled shipments up 18%; Automotive extruded shipments up 16%
- Muscle Shoals operational integration progressing well, still working through metal administration issues
- Q2 2015 Diluted EPS of (€0.45), EPS not taking into account unrealized gains on derivatives of (€0.61)
Constellium’s second quarter 2015 results comprise a record Adjusted EBITDA in our AS&I segment and better than anticipated results in our A&T business. We also achieved record shipments and Adjusted EBITDA in P&ARP due to the acquisition of Wise Metals in January 2015.
Revenues for the second quarter 2015 were €1.375 billion, an enhance of 49% from the second quarter 2014, of which €308 million were contributed by Muscle Shoals. Adjusted EBITDA was €93 million, counting €19 million from Muscle Shoals. This is an enhance of 15% from the second quarter 2014 Adjusted EBITDA of €81 million. For the six months ended June 30, 2015, Constellium stated Adjusted EBITDA of €188 million, counting €44 million from Muscle Shoals contrast to €152 million for the same period in 2014. Second quarter 2015 shipments were 386k metric tons, an enhance of 38% from second quarter 2014, of which 111k metric tons were contributed by Muscle Shoals. Adjusted EBITDA per metric ton for the second quarter 2015 was €241 contrast to €291 for the second quarter 2014.
Constellium N.V. is engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products for the aerospace, packaging, and automotive end-markets. The company operates in three segments: Aerospace & Transportation, Packaging & Automotive Rolled Products, and Automotive Structures & Industry.
Shares of OvaScience Inc (NASDAQ:OVAS), declined -7.59% to $23.00, during its last trading session.
OvaScience, stated second quarter 2015 financial results and highlighted recent accomplishments, counting additional healthy births with the AUGMENTSM treatment at all clinics presently offering the treatment. In addition, the AUGMENT treatment will be accessible in Spain through the largest in vitro fertilization (IVF) clinic network in the world, in addition to through another new clinic partnership in Latin America. The Company is also on track to meet the 2015 aims for the OvaPrime and OvaTure treatments. The AUGMENT treatment is not accessible in the United States.
Second Quarter and Recent Highlights
- Births at All IVF Clinics Offering the AUGMENT Treatment
TIME magazine featured the first baby born with the AUGMENT treatment to a woman in Canada who had repeatedly failed fertility treatments over four years. Since then, IVF clinics in Turkey and the United Arab Emirates (UAE) have also stated healthy births. More babies are predictable this year in the IVF clinics presently offering the AUGMENT treatment.
- Additional Positive Patient Experiences with the AUGMENT Treatment
All the IVF clinics offering the AUGMENT treatment have stated improved pregnancy rates and healthy births in poor prognostic women. For the first time, Michael Fakih, M.D., Founder and Chairman of Fakih IVF, shared his initial experiences in 59 women with poor egg health and embryo quality who failed an average of four preceding IVF cycles. Following the AUGMENT treatment, clinical pregnancy rates in these women raised to 22 percent from 4 percent when contrast to their preceding total IVF cycles, and there were 11 ongoing pregnancies, or about 18 percent, as compared to a preceding live birth rate of 2 percent.
- AUGMENT Treatment Now Accessible to Patients in New International Regions
In an earlier than planned planned expansion, the AUGMENT treatment will be made accessible through an initial preceptorship program at IVI Valencia, a leading IVF clinic in Spain that is part of the IVI Group of 38 clinics spanning nine countries, which is the largest IVF clinic network in the world. In addition, OvaScience will also start offering its AUGMENT treatment through a partnership with Growing Generations Panama, under the medical directorship of Bradford Kolb, M.D., F.A.C.O.G., and with IVF Centro de Reproducción, under the medical directorship of Mario Vega, M.D. Growing Generations Panama is an established international partner of leading fertility services provider Growing Generations and serves fertility patients in the greater Latin American region and beyond.
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The companys patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
At the end of Friday’s trade, Shares of OM Group, Inc. (NYSE:OMG), gained 0.27% to $33.56.
OM Group, declared that at a special meeting, stockholders voted to approve the proposal to adopt the merger agreement reached with funds managed by associates of Apollo Global Administration, LLC (APO) and an associate of Platform Specialty Products (PAH).
On June 1, 2015, OM Group, Apollo and Platform declared that they had reached the definitive merger agreement under which Apollo will acquire OM Group for $34.00 per share in cash, representing an about 28% premium above OM Group’s closing share price on May 29, 2015, the last trading day preceding to the declarations of the merger. Platform will acquire OM Group’s Electronic Chemicals and Photomasks businesses from Apollo. Following the transactions, Apollo will own OM Group’s Magnetic Technologies, Battery Technologies and Advanced Organics businesses.
The transactions are subject to customary closing conditions, in addition to obtaining regulatory approvals in various jurisdictions. Completion of the acquisition is predictable by the end of 2015.
OM Group, Inc. operates as a technology-driven industrial company worldwide. It operates through Magnetic Technologies, Battery Technologies, and Specialty Chemicals segments. The Magnetic Technologies segment develops, manufactures, and distributes industrial-use magnetic materials, and related products and systems.
Finally, Qlik Technologies Inc (NASDAQ:QLIK), ended its last trade with 1.80% gain, and closed at $41.92.
Qlik (QLIK), declared that Eternit-Werke Ludwig Hatschek AG, has selected QlikView to drive raised visibility into its sales performance and supply chain data with assist from Qlik Elite Solution Partner, Data GmbH.
QlikView provides a visually appealing, user-friendly business intelligence (BI) solution that gives Eternit the transparency, consistency, and effective information they need across their various administration levels and divisions. The QlikView solution complements their SAP® ERP system with a comprehensive BI solution that allows users to map data of different product groups into a single platform while ensuring scalability and speed. This detailed view of its SAP data, counting sales and revenue per customer, enables Eternit to detect changes in customer behavior and discover trends in the product life cycle almost right away.
“With QlikView, we have found a solution that not only provides a single source of truth, but also encourages use due to its visual nature. Now, anyone can talk concretely about the state of our business,” said Daniel Müller, Head of Controlling and Logistics, Eternit-Werke. “Formerly, it required two hours to prepare data from our ERP system and recently with Qlik it takes less than 10 minutes.”
Qlik Technologies Inc. provides user-driven business intelligence solutions that enable customers to make business decisions. The company develops, commercializes, and implements software products and related services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
